Separate Crohn's Outcomes Positive
Trials With ABT-199 Held Up; Patient Death on AbbVie Drug?
Backing up the European approval of Humira (adalimumab) with more data, Abbott spinout AbbVie for the first time offered long-term, patient-reported health outcomes data from the Phase III IMAgINE-1 trial in young people with Crohn's disease, along with favorable results of a caregiver survey.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.